Undisclosed CNS Program(s)
Genetic Neurological Disease(s)
Key Facts
About Editpep
Editpep is a private, pre-clinical stage biotech developing a novel non-viral delivery platform, PERC™, for CRISPR gene editing in vivo. The platform, exclusively licensed from UC Berkeley, is engineered for high-efficiency editing in hard-to-treat tissues like the brain, with advantages in safety, scalability, and cargo flexibility. The company is leveraging its technology to build a pipeline of CNS-targeted therapies and is actively seeking partnerships to expand its reach into other therapeutic areas.
View full company profileAbout NW PharmaTech
NW PharmaTech is a private, clinical-stage biotech founded in 2015, developing improved therapeutics for mental health conditions using its proprietary micelle-based drug delivery technology. The company is advancing a pipeline within the CNS space, with programs targeting conditions like anxiety and psychosis, and is preparing for Phase IIB trials. It operates with a pre-revenue business model, leveraging academic partnerships and a specialized team to bring enhanced, cost-effective treatments to a large and underserved market.
View full company profileAbout Biomia
Biomia is a preclinical-stage biotech leveraging a rational engineering approach to develop nature-inspired small molecules for CNS disorders. Based in Copenhagen and founded in 2017, the company operates as a private, pre-revenue entity building a therapeutic pipeline from its proprietary discovery platform. Its strategy involves translating complex natural product pharmacophores into druggable candidates with improved properties for challenging neurological targets.
View full company profileAbout Kesmalea Therapeutics
Kesmalea Therapeutics is a private, preclinical-stage biotech leveraging its innovative SELFTAC® platform to create a new class of oral, CNS-penetrant protein degraders. The company aims to solve the 'size problem' associated with traditional bifunctional degraders by designing small molecules that self-assemble into active degraders in situ. Backed by a £25 million Series A round co-led by Syncona and Oxford Science Enterprise, Kesmalea is building a pipeline in oncology and CNS with a seasoned leadership team. The company's approach could significantly expand the clinical applicability of targeted protein degradation.
View full company profile